Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brendan Reardon

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
JCO Precision Oncology|September 8, 2022
Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid CancerJulia Schiantarelli, Theodora Pappa, Jake Conway, et al.
Nature Cancer|February 5, 2022
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncologyBrendan Reardon, Nathanael D Moore, Nicholas S Moore, et al.
Genome Medicine|July 28, 2016
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicineAndrea Garofalo, Lynette Sholl, Brendan Reardon, et al.
Cancer Discovery|June 18, 2021
Discovery and Features of an Alkylating Signature in Colorectal CancerCarino Gurjao, Rong Zhong, Koichiro Haruki, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/DocetaxelKendrick Yim, Matias Vergara, Jihyun Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell CarcinomaKent W Mouw, James M Cleary, Brendan Reardon, et al.
NPJ Precision Oncology|April 28, 2026
Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancerDavid D Chen, Anat Zimmer, David D Yang, et al.
Cancer Cell|January 16, 2026
A context-augmented large language model for accurate precision oncology medicine recommendationsHyeji Jun, Yutaro Tanaka, Shreya Johri, et al.
Cancer Research|September 2, 2020
Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder CancerJoaquim Bellmunt, Jaegil Kim, Brendan Reardon, et al.
Cancer|August 9, 2020
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinomaVictor McPherson, Brendan Reardon, Aravind Bhayankara, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
JCO Precision Oncology|September 8, 2022
Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid CancerJulia Schiantarelli, Theodora Pappa, Jake Conway, et al.
Nature Cancer|February 5, 2022
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncologyBrendan Reardon, Nathanael D Moore, Nicholas S Moore, et al.
Genome Medicine|July 28, 2016
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicineAndrea Garofalo, Lynette Sholl, Brendan Reardon, et al.
Cancer Discovery|June 18, 2021
Discovery and Features of an Alkylating Signature in Colorectal CancerCarino Gurjao, Rong Zhong, Koichiro Haruki, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/DocetaxelKendrick Yim, Matias Vergara, Jihyun Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell CarcinomaKent W Mouw, James M Cleary, Brendan Reardon, et al.
NPJ Precision Oncology|April 28, 2026
Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancerDavid D Chen, Anat Zimmer, David D Yang, et al.
Cancer Cell|January 16, 2026
A context-augmented large language model for accurate precision oncology medicine recommendationsHyeji Jun, Yutaro Tanaka, Shreya Johri, et al.
Cancer Research|September 2, 2020
Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder CancerJoaquim Bellmunt, Jaegil Kim, Brendan Reardon, et al.
Cancer|August 9, 2020
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinomaVictor McPherson, Brendan Reardon, Aravind Bhayankara, et al.
Pageof 5